ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer. The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer. Revolution Medicines’ daraxonrasib meaningfully extends the overall survival at a rate that is higher than many frontline chemotherapy regimens achieve. Image credit: [lassedesignen]/Shutterstock.com At the 2026 American Society of Clinical Oncology (ASCO) annual congress, topline data from the Phase III RASolute 302 was presented at the plenary session. At an 8.5-month follow-up all primary and secondary endpoints were met. Previously treated metastatic pancreatic cancer…

Source: Clinical Trials Arena